



## Altimune to Announce Second Quarter 2019 Financial Results on August 14

August 5, 2019 at 7:00 AM EDT

GAITHERSBURG, Md., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and six months ended June 30, 2019 before the market open and host a conference call on Wednesday, August 14, 2019.

### **Conference Call Details**

Date: Wednesday, August 14  
Time: 8:30 am Eastern Time  
Domestic: 877-423-9813  
International: 201-689-8573  
Conference ID: 13692577  
Webcast: <http://public.viavid.com/index.php?id=135358>

### **About Altimune**

Altimune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™ and NasoShield™). For more information on Altimune, please visit [www.altimmune.com](http://www.altimmune.com).

### **Contacts:**

Will Brown  
Chief Financial Officer  
Phone: 240-654-1450  
[wbrown@altimmune.com](mailto:wbrown@altimmune.com)

Ashley R. Robinson  
LifeSci Advisors, LLC  
617-535-7742  
[arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)



Source: Altimune, Inc.